First phase 1 starters challenge Pluvicto and Revolution
The latest first-in-human trial entrants include several novel mechanisms, a PSMA radioconjugate and a new pan-KRAS challenger.
Triple meeting 2023 – Revolution’s KRAS revolution promise draws fans
Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients.
Triple meeting 2023 – PRMT5 has a wobble
Initial data on Amgen’s AMG 193 give some Tango investors a headache.
Triple meeting 2023 – Relay shifts to a tumour-agnostic plan
The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.
Triple meeting 2023 – a p53 double-whammy for PMV
Data on PMV’s p53 reactivator prompt a 26% selloff before their presentation, and 48% afterwards.
Tempest kicks up a storm as Morpheus strikes again
Tempest Therapeutics confirms an earlier success with its lead project, and this time investors respond.
Sana shelves its in vivo Car-T
The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.
